

SEARCH REQUEST FORM

58344

Requestor's Name: Natalie Davis Serial Number: 09/674436
 Date: 1-14-02 Phone: 308-6410 Art Unit: 1642
Mailbox 8E12 MED

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Please search SEQ ID NO: 1 and for
 the gene "Any-RF" which may be derived
 from *Anthonrea yamamai* OR a
 dormancy-control substance, which
 prevents insects from going into
 dormancy in the fall.


SEQ ID NO: = Asp-Ile-Leu-Arg-Gly

BEST AVAILABLE COPY

part 1

STAFF USE ONLY

Date completed: <u>1/23</u>	Search Site	Vendors
Searcher: <u>056-602-303-4292</u>	<input type="checkbox"/> STIC	<input checked="" type="checkbox"/> IG Suite
Terminal time: <u>21</u>	<input checked="" type="checkbox"/> CM-1	<input checked="" type="checkbox"/> STN 5245
Elapsed time: <u>11</u>	<input type="checkbox"/> Pre-S	<input type="checkbox"/> Dialog
CPU-time:	<input type="checkbox"/> N.A. Sequence	<input type="checkbox"/> APS
Total time:	<input checked="" type="checkbox"/> A.A. Sequence	<input type="checkbox"/> Geninfo
Number of Searches:	<input type="checkbox"/> Structure	<input type="checkbox"/> SDC
Number of Databases: <u>7</u>	<input type="checkbox"/> Bibliographic	<input checked="" type="checkbox"/> DARC/Questel
		<input checked="" type="checkbox"/> Other <u>Computer</u>



=> fil hcplus
FILE 'HCAPLUS' ENTERED AT 15:48:09 ON 23 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 23 Jan 2002 VCL 136 ISS 4
FILE LAST UPDATED: 21 Jan 2002 (20020121/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCplus now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1996.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles Thesaurus (/KL field) in this file.


= d q.e 17

L1 21 SEA FILE=REGISTRY.DILRG/SQSP
L2 153 SEA FILE=HCAPLUS L1
L3 300 SEA FILE=HCAPLUS ANTHEREA OR ANTHERAEA
L4 111 SEA FILE=HCAPLUS YAMAMAI
L5 9212 SEA FILE=HCAPLUS DORMANT OR DORMANCY
L6 47404 SEA FILE=HCAPLUS LAFVA?
L7 2 SEA FILE=HCAPLUS L2 AND ((L3 OR L4 OR L5 OR L6))

= d bip abs 17 1-2

L ANTHONY T OF 2 HCAPLUS COPYRIGHT 2002 ACS
A1 20020121/ED HCAPLUS
D1 1.3:131471
T1 Silkworm diapause regulatory gene Aky-FF and method of isolation of its protein product
IN Kotaki, Toyomi; Tsukada, Masuniro; Suzuki, Keiichi; Yang, Ping
PA Nenrin Seisansho Sanshi Konchu Nesyo Gijutsu Kenkyusho, Japan
SO Jpn. Tokkyo Koho, 12 pp.
CREFID: 177841
PT Parent
LA Japanese
HAN. 'NT' A


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002-131471	A1	2002-01-12	2001-09-13	2002-01-12
JP 2002-131474	A1	2002-01-12		



WO 2000073441 A1 20001207 WO 2000-JP3388 20000526
W: CA, US
RW: DE, FR, GB
EP 1101519 A1 20010513 EP 2000-931578 20000526
R: DE, FR, GB, SI, LT, LV, RO
PRAI JP 1999-152273 A 19990511
JP 2000-81312 A 20000312
WO 2000-JP3388 W 20000516
AB Silkworm **Any-SF** gene involved in diapause regulation, and method of isolation of its protein product, are disclosed. A protein isolated from silkworm **Antheraea yamamai** using RP-HPLC and ion exchange HPLC and its C-terminally amidated peptide fragment demonstrated diapause regulatory activity.

LT AMERICAN POURNAL OF SCIENCE AND TECHNOLOGY
AN ISSN: 1062-1024
LN 10(1), 1-11
TI A nuclear juvenile hormone-binding protein from **larvae** of *Manduca sexta*: a putative receptor for the metamorphic action of juvenile hormone
AU Palai, Subba R.; Touhara, Kizushige; Charles, Jean-Philippe; Bonning, Bryony C.; Atkinson, Jeffrey K.; Trowell, Stephen C.; Hiruma, Kiyoshi; Goodman, Walter G.; Kyriakides, Themis; et al.
CS Dep. Ecology, Univ. Washington, Seattle, WA, 98195, USA
SO Proc. Natl. Acad. Sci. U. S. A. (1994), 91(15), 6191-5
CODEEN: PNAA6; ISSN: 0027-8424
DT Journal
LA English
AB A 1.1-kb nuclear juvenile hormone (JH)-binding protein from the epidermis of *Manduca sexta* **larvae** was purified by using the photo-affinity analog for JH II (18ⁱH-epoxyhomofarnesyl diazoacetate) and partially sequenced. A 1.1-kb cDNA was isolated by using degenerate oligonucleotide primers for PCR based on these sequences. This cDNA encoded a 262-amino acid protein that showed no similarity with other known proteins, except for short stretches of the interphotoreceptor retinoid-binding protein, rhodopsin, and human nuclear protein p68. Recombinant baculovirus contg. this cDNA made a 29-kDa protein that was covalently modified by [³H] epoxyhomofarnesyl diazoacetate and specifically bound the natural enantiomer of JH I ($K_i = 10.7 \text{ nM}$). This binding was inhibited by the natural JHs but not by methoprene. Immunocytochem. anal. showed localization of this 29-kDa protein to epidermal nuclei. Both mRNA and protein are present during the intermolt periods; during the **larval** molt, the mRNA disappears but the protein persists. Later when cells become pupally committed, both the mRNA and protein disappear with a transient peak around near pupal ecdysis. The properties of this protein are consistent with its being the receptor necessary for the first metamorphic effect of JH.

= fil 23m
FILE 'HOME' ENTERED AT 15:18:59 ON 23 JAN 2002



Davis, N.
C91674434

09/674436

L1 FILE 'REGISTRY' ENTERED AT 10:59:43 ON 23 JAN 2002
210 S DILRG/SQSP

L2 FILE 'CAPLUS' ENTERED AT 11:00:05 ON 23 JAN 2002
155 S L1

L4 3 S L2 AND RF
L5 2 S L2 AND DIAPAUSE
L6 4 S L4 OR L5


L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:364016 CAPLUS
DOCUMENT NUMBER: 135:1093
TITLE: The malaria genome sequencing project: Complete sequence of Plasmodium falciparum chromosome 2
AUTHOR(S): Gardner, M. J.; Tettelin, H.; Carucci, D. J.; Cummings, L. M.; Smith, H. O.; Fraser, C. M.; Venter, J. C.; Hoffman, S. L.
CORPORATE SOURCE: The Institute for Genomic Research, Rockville, MD, 20850, USA
SOURCE: Parassitologia (Roma, Italy) (1999), 41(1-3), 69-75
CODEN: PSSGAR; ISSN: 0048-2951
PUBLISHER: Lambardo Editore
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An international consortium has been formed to sequence the entire genome of the human malaria parasite Plasmodium falciparum. Chromosome 2 of clone 3D7 was sequenced using a shotgun sequencing strategy. Chromosome 2 is 947 kb in length, has a base compn. of 80.2% A+T, and contains 210 predicted genes. In comparison to the Saccharomyces cerevisiae genome, chromosome 2 has a lower gene d., a greater proportion of genes contg. introns, and nearly twice as many proteins contg. predicted non-globular domains. A group of putative surface proteins was identified, rifins, which are encoded by a gene family comprising up to 7% of the protein-encoding genes in the genome. The rifins exhibit considerable sequence diversity and may play an important role in antigenic variation. Sixteen genes encoded on chromosome 2 showed signs of a plastid or mitochondrial origin, including several genes involved in fatty acid biosynthesis. Completion of the chromosome 2 sequence demonstrated that the A+T-rich genome of P. falciparum can be sequenced by the shotgun approach. Within 2-3 yr, the sequence of almost all P. falciparum genes will have been detd., paving the way for genetic, biochem. and immunol. research aimed at developing new drugs and vaccines against malaria.

IT 257896-56-3

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; complete sequence of Plasmodium falciparum chromosome 2)
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:772766 CAPLUS
DOCUMENT NUMBER: 133:330556



09/674436

TITLE: Genome sequence and polypeptides of *Pyrococcus abyssi* and their uses
INVENTOR(S): Forterre, Patrick; Thierry, Jean-Claude; Prieur, Daniel; Dietrich, Jacques; Lecompte, Odile; Querellou, Joel; Weissenbach, Jean; Saurin, William; Heilig, Roland; Flament, Didier; Raffin, Jean-Paul; Henneke, Ghislaine; Gueguen, Yannick; Rolland, Jean-Luc
PATENT ASSIGNEE(S): Centre National de la Recherche Scientifique (CNRS), Fr.; Institut Francais de Recherche pour l'Exploitation de la Mer - IFREMER
SOURCE: PCT Int. Appl., 1403 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000065062	A2	20001102	WO 2000-FR1065	20000421
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2792651	A1	20001027	FR 1999-5034	19990421

PRIORITY APPLN. INFO.: FR 1999-5034 A 19990421

AB The invention relates to the genome sequence of *Pyrococcus abyssi* strain Orsay, the 807 open reading frame nucleotide sequences coding for polypeptides of *P. abyssi* such as polypeptides involved in metab. or in the replication process, in addn. to vectors including said sequences and cells transformed by said vectors. Replication factor C (large and small forms resulting from intein splicing), PCNA (proliferating cell nuclear antigen), DNA polymerase II large and small subunits, replication factor A, and DNA polymerase I were isolated and characterized by recombinant cloning in *Escherichia coli*. The invention also relates to methods using said nucleic acids or polypeptides, esp. biosynthesis methods or biodegrdn. methods for mols. of interest and to kits comprising said polypeptides.

IT 302870-69-5


RL: BOC (Biological occurrence); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; genome sequence and polypeptides of *Pyrococcus abyssi* and their uses)

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:522576 CAPLUS

DOCUMENT NUMBER: 133:131471

TITLE: Silkworm **diapause** regulatory gene Any-
RF and method of isolation of its protein product



09/674436


INVENTOR(S): Kotaki, Toyomi; Tsukada, Masuhiro; Suzuki, Koichi; Yang, Ping
PATENT ASSIGNEE(S): Norin Suisansho Sanshi Konchu Nogyo Gijutsu Kenkyusho, Japan
SOURCE: Jpn. Tokyo Koho, 12 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 3023790	B1	20000321	JP 1999-152273	19990531
JP 2000342254	A2	20001212		
WO 2000073441	A1	20001207	WO 2000-JP3388	20000526
W: CA, US RW: DE, FR, GB EP 1101819	A1	20010523	EP 2000-931578	20000526
R: DE, FR, GB, SI, LT, LV, RO				
PRIORITY APPLN. INFO.:			JP 1999-152273	A 19990531
			JP 2000-81012	A 20000322
			WO 2000-JP3388	W 20000526

AB Silkworm Any-RF gene involved in **diapause** regulation, and method of isolation of its protein product, are disclosed. A protein isolated from silkworm Antheraea yamamai using RP-HPLC and ion exchange HPLC and its C-terminally amidated peptide fragment demonstrated **diapause** regulatory activity.
IT 286408-63-7
RL: BOC (Biological occurrence); BPR (Biological process); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(amino acid sequence; silkworm **diapause** regulatory gene Any-RF and method of isolation of protein product)

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:505667 CAPLUS
DOCUMENT NUMBER: 129:229492
TITLE: Cloning of leukemia inhibitory factor (LIF) and its expression in the uterus during embryonic **diapause** and implantation in the mink (*Mustela vison*)
AUTHOR(S): Song, Jian H.; Houde, Alain; Murphy, Bruce D.
CORPORATE SOURCE: Cent. Recherche Reproduction Animale, Fac. Med. Veterinaire, Univ. Montreal, St-Hyacinthe, PQ, J2S 7C6, Can.
SOURCE: Mol. Reprod. Dev. (1998), 51(1), 13-21
CODEN: MREDEE; ISSN: 1040-452X
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Leukemia inhibitory factor (LIF) is essential for embryo implantation in mice. Whether LIF plays a role in termination of embryonic **diapause** and initiation of implantation in carnivores, esp. in species with obligate delayed implantation such as the mink, is not known. The objectives of this study were to clone the LIF coding sequence in the mink and det. its mRNA abundance in the uterus through embryonic **diapause**,



09/674436

implantation, and early postimplantation. The authors show that the mink LIF cDNA contains 609 nt encoding a deduced protein of 203 amino acids. The homologies are 80.6, 90, 88.2, 87.6, and 86.8% in coding sequence and 79.2, 90.1, 91, 90.1 and 85.4% in amino acid sequence with mouse, human, pig, cow, and sheep resp. Glycosylation sites and disulfide bonds present in other species are generally conserved in the mink LIF sequence. Quantitation by polymerase chain reaction amplification indicates that LIF mRNA is expressed in mink uterus just prior to implantation and during the first two days after implantation, but not during **diapause** or later after implantation pregnancy. The abundance of LIF mRNA was significantly higher in the uterus at the embryo expansion stage than at days 1-2 of postimplantation. By immunohistochem. localization it was shown that LIF is expressed in the uterine epithelial glands at time of embryonic expansion and in early postimplantation. The coincidence of LIF expression with implantation in this species suggests that LIF is involved in the implantation process, and may be a maternal signal which terminates obligate embryonic **diapause**.

IT 212846-19-0

RL: PRP (Properties)

(amino acid sequence; cloning of leukemia inhibitory factor (LIF) and expression in uterus during embryonic **diapause** and implantation in mink (*Mustela vison*))

E1 THROUGH E4 ASSIGNED

~~FILE~~ 'REGISTRY' ENTERED AT 11:03:47 ON 23 JAN 2002

L7 4 SEA FILE=REGISTRY ABB=ON PLU=ON (212846-19-0/BI OR
257896-56-3/BI OR 286408-63-7/BI OR 302870-69-5/BI)

=> s 17 and 11

L8 4 L7 AND L1

L8 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2002 ACS

RN 302870-69-5 REGISTRY

CN Protein ORF 756 (*Pyrococcus abyssi* strain Orsay) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 457: PN: WO0065062 SEQID: 756 claimed protein

CI MAN

SQL 310

SEQ 1 MVVSMREGEI ISLFMKHFER HSLGDDAGFI KLNNSWLLVT SDMLVWKTDV
51 PDFMTPEDAG RKVVVTMVSD IAAMGGRPMA FFFSLAVPGD VSEDILRGIA
=====

101 RGINEGSKVY KLKIVSGDTN EADDIIDGG SLGIGKRLLL RSNAKPGDLV
151 CVTGDGRPL TALLLWMRGE KIPREIEEKA RNPRARVEEG VKLSSLANSA
201 IDISDGGLSKE LWEIANASNV RIIIEERLP ISDSVKEIVS DPVKVALASG
251 EEFELLFTIP REKVEELDID FKIIGRVEGG NGVYIKRGRK IEELEVLGWE
301 HLAGGIDVEL


HITS AT: 94-98

REFERENCE 1: 133:330556

I.8 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2002 ACS

RN 286408-63-7 REGISTRY

CN Glycine, L-.alpha.-aspartyl-L-isoleucyl-L-leucyl-L-arginyl- (9CI)
(CA INDEX NAME)



09/674436

OTHER NAMES:

CN 1: PN: JP3023790 PAGE: 9 claimed sequence
CN Protein gene Any-RF (Antheraea yamamai fragment)
SQL 5

SEQ 1 DILRG
=====

HITS AT: 1-5

REFERENCE 1: 133:131471

L8 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2002 ACS

RN 257896-56-3 REGISTRY

CN Phosphatase (acid phosphatase family) (Plasmodium falciparum gene PFB0380c) (9CI) (CA INDEX NAME)


OTHER NAMES:

CN 5: PN: WO0025728 SEQID: 75 claimed protein
CN GenBank AE001391-derived protein GI 3845169
CN Phosphatase, acid (Plasmodium falciparum clone 3D7 gene PFB0380c)
CN Protein (Plasmodium falciparum clone p3D7 chromosome 2 gene PFB0380)
CI MAN
SQL 2010

SEQ 1 MLIKQEPKEV EKKEEKEKKG AKDKGKDLS LNKKRERKKK ESQKIDRYLI
51 NSCDSNKSNSY SCCYLNNNECF VKNISICKKC MFSYFEFKNV TKVIYMRHGA
101 RTPKKKIKNI WPFKEKGDL TFLGFQQSIK VGEYLRKYYY TFNKLNKKYN
151 KRERGLRINN KEKGYIKKKN CDVKKCKTLY KNKYNNNNNN NNNNNYVINEK
201 YNGSNKNDYV KNNTYDNKGY SYLYDLSTSF NELENRKRKL HKFPYLRDFI
251 YYEKYFLKIN KRSNKHQRKV FIKIKRRRRN NILKWIHQH LINKMKKIKN
301 KNMNNYNKCY IKFSSIRKRG YHKMENIECN NKNNDNNND DNNNNNNNDN
351 NNNNNDDNNN DDNNNDNNNN NDDNNNNNNND DDNNYYYYNY NNDETPFNNK
401 SFNYADMKY TKYYYKNILK DKKNIYTNNK KKELFFPLME HLYMYKKLL
451 INKMKEKNIK KKKKKYDKII KLINKYLCIK TTNSERCKLT AYGIICGILG
501 ISEYIYFFF ILFFKSNSYDK TNDNNIDTYT KRKEKKKCLN KRSKCFQNW
551 LNRDITSGQY NCIDKNTAPV KNYIIGENLC GENCGKNGC GDILRGDILC
=====

601 GDILRGDNNS IPLFRSNRIF CKQSKITFC D ELYIYFNKIL KRLQSLDDMY
=====

651 KINHEVKMFG NDKDVLNNSY KKCYDKNDYG SYPSPNKYSN DYKSHYVIKK
701 MKNVKSVQCS NESIILKERQ ENEKKKKKKK KKMENTFTNN NNIMYNINV
751 FDLIINERGN FQFFYNNNIKK KRQKNEKGLE EWNVYNIFQL YMKYILNEFS
801 KFFKLFKFLN KNVENIDNTF NSITNIYNKY YINMMVHRKD CFEKKQIHSK
851 EHMMKKIHLR DKFIEYEKEN EIIDNCNIN MDNKKKEINN NYNNMIDNNN
901 IEIDMSNNFI FTYYYIFYLL NYMDTYIQFL FYYLKNTYIL FSVVKAERN
951 SLMLKTLTK NHYIKKLRNH IIHNSDVYKI LNYYKDEIF IVYDITKWTE
1001 NCMNTTDILY NDVKNTKID DLENIDIPPI TNDKEEYHVN NSIISVLKKH
1051 NSSVYKLKKK LKNSIILKDL KKLNCNFINK NYIHTNYDK HNKIYQDKIK
1101 NWTYHPFHNK KKNVKKIJKF ISAYDAYIYH GVNLNLNFNR AYEKLSQHPP
1151 SSIDLKKEY GQNNYIINGE IKKYEEQNNF IIKRPNINIS GKNLSCHNKT
1201 NSSNTLQGND FEANILADE RTRLKRNKNI QNRAKVNQGM TINNNNSKKYR
1251 NNQTEYYKKK EKKKKYDQKN DQTNEQKCAQ KNDQTNEQKN DQTNDQTNDQ
1301 TNDQTNDQTN DQTNDKIKRF YKNIYTCYKL MCKNEYSNKY LSWLCGMSL
1351 IDVVVINFIIN VFLYEKYNKE NKTTKCFIPR IILYLTHQSS ILSFQSCVGI
1401 RKKDMKIPPF ASFISLEIH IKKKKIKNLS NKLCNVSNNE KSYCYSNKYN
1451 IMKGEKKKHA SSRSVHVNPQT DRTDVLSFIY HNNNTANIFCC KDDCVWKVRE
1501 TENEKKFEKC EKNKKFMNNE NENVIKDDEK NIYNILKRNI NENIDKKKS
1551 NINTCIYNDI PTNVNNKKYE SYLPKCLNKI HDFKNLFYLL CYKNNNIQDL
1601 IQLYDICLNN NYTHIKKNMQ LKEGKKHGKR NFYGYFVKFT FNNSVPLKLK



09/674436

1651 KNKLIKYYNM GNKKDKEEDN NYHNDKNNSY DNIFYDNHDT NNNNNNNNNN
1701 NNNSNNNNNN NICLKNNKNN IMHEDINANK RESLKKKKKK KKKNCIQKNN
1751 NICERKKNSI HNNSSKYIFN TVRFFKMKDI AKINTNKKCD ENSISCINNM
1801 REKRNI FKNL NRNI LNFNNS NNDKYMNYIY NSTNVTYGKN YKRINKKD
1851 INNILLHTYK QHKKKKSTII SSDNNNNNNN NAEDDISSRK LKFKDIKGNT
1901 KQKYINDHNN INSYDNNINN GLINEHKNVL HNECKNKNQ IIGYSIKYDK
1951 NVVSENSCSD VITSLKDKKI KKRKKKLQKK NYENENIVCL DCLISYLKKM
2001 LRIYGNPEIL

HITS AT: 592-596, 602-606

REFERENCE 1: 135:1093

REFERENCE 2: 132:330627

REFERENCE 3: 132:147372

L8 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2002 ACS

RN 212846-19-0 REGISTRY

CN Leukemia inhibitory factor (Mustela vison gene LIF) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN GenBank AF048827-derived protein GI 2959710

CI MAN

SQL 202


SEQ 1 MKVLAAGVVP LLLVLHWKHG AGTPLPITPV NATCATRHPC HSNLMNQIRN
51 QLAHVNGSAN ALFILYYTAQ GEPFPNNLDK LCGPNVTDFP PFHRNGTEKT
101 RLVELYRIIA YLGASLGNIT RDQKVLPNA LSLHSKLKAT ADILRGLLSN
=====

151 VLCRLCNKYH VAHV DVAYGP DTSGKDVFQK KKLGCQLLGK YKQVIAVVAQ
201 AF

HITS AT: 142-146

REFERENCE 1: 129:229492

FILE 'HOME' ENTERED AT 11:04:12 ON 23 JAN 2002



卷之三

1. *W. E. H. LEWIS*, *1920-1921*
2. *W. E. H. LEWIS*, *1921-1922*

THE INVENTION AND USE OF
THE NUMBER LINE, NUMBER
SQUARE, AND NUMBER
CIRCLE.

RECEIVED
APRIL 14 1941
U. S. GOVERNMENT PRINTING OFFICE
1941 14-1000-1

THE JOURNAL OF CLIMATE

卷之三

卷之三

1. *W. L. BURKE*, *1864-1941*
2. *W. L. BURKE*, *1864-1941*


THE NATION AND THE NUMBER

THE BOSTONIAN, A MONTHLY MAGAZINE OF LITERATURE, SCIENCE, AND POLITICS.

Wed Jan 23 07:27:23 2002

us-09-674-436-1.rapm

RECEIVED
FEDERAL BUREAU OF INVESTIGATION
U.S. DEPARTMENT OF JUSTICE
WASH. D.C.
SEARCHED INDEXED SERIALIZED FILED
FEB 26 2002



the K^+ concentration in the medium ($[K]$) is increased from 10^{-4} to 10^{-3} M, the rate of O_2 uptake increases by a factor of 2.5.

卷之三

卷之三

卷之三

the first time in the history of the world, the people of the United States have been compelled to go to war to defend their country.

the first time in the history of the world, the people of the United States have been compelled to make a choice between two political parties.

and the author's name, and the date of publication.

PE
 XX
 PE o-³-Fib 1994
 PA
 XX
 (AMEA) AMEA + Bp L11.
 PA
 XX
 Growth NM. Taff. as Bp. Monocult. No.
 PR WH1; 1994 Z/368/9/34.
 XX
 PR New receptor binding determinants from
 P1 factor - useful for designing viral genes
 XX
 PS -resistance; p19; 59P; Erst ist.
 XX
 CC The sequences of mouse, rabbit, swine, human
 CC L1F proteins and of human CSP (FAV) are
 CC receptor-binding determinants are based
 CC on sequence.

$$\begin{aligned} \text{N}(\tilde{\alpha}) &= \lambda^{n+1} \cdot \text{N}(\alpha) \cdot \text{K}^{-1}(M), \\ \text{N}(\tilde{\beta}) &= \lambda^{n+1} \cdot \text{N}(\beta) \cdot \text{K}^{-1}(M), \\ \text{N}(\tilde{\gamma}) &= \lambda^{n+1} \cdot \text{N}(\gamma) \cdot \text{K}^{-1}(M). \end{aligned}$$

19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1

Table 2. *Effect of Dose on Activity of Amphotericin B against *Candida albicans* and *Cryptococcus neoformans* and of Dose and Time of Administration on the Proportion of Cells with the Maximum Number of Pseudohyphae after 48 h of Treatment.*

the first time in the history of the world, the people of the United States have been compelled to make a choice between two political parties, each of which has a distinct and well-defined platform, and each of which has a definite and well-defined object in view. The people of the United States have been compelled to make a choice between two political parties, each of which has a distinct and well-defined platform, and each of which has a definite and well-defined object in view.

IP	0-3-FEB	19:41:	34W	AU0000041
XX				
PR				
0-3-FEB	19:41:		34W	AU0000041
XX				
PA				
(AMPA)	AMPA!	0-3-FEB	19:41:	34W
XX				
P-1	Growth RM.	19:41:	34W	AU0000041
XX				
DR	WPI:	19:41:	27:368#/#34.	
XX				
P-1	New receptor binding structures			
PR	labeled - testable for desaminase			
XX				
P-1	4-18:10:00: 19:41: 27:364#/#34			
PS				
XX				
CC	The sequence contains no mouse amino acid			
CC	1-18 proteins, start of human amino			
CC	receptor-binding determining			
CC	sequence.			
XX				
SU	Sequence	1st AA:		

1944-1945
1945-1946

RESULTS FROM THE
INITIAL STAGES
TEST.

McGraw-Hill, New York, 1960.

19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1

Model Number: 4-1
Model Number: 4-2
Model Number: 4-3

the first time that the results of the treatment were published. No other author has reported such a large number of cases as Aebischer and his colleagues did in their comprehensive study. The results of the treatment were evaluated according to the following criteria: improvement, no improvement, deterioration, and death. The most important finding was that the improvement rate was 60% in the patients who had been treated with the new therapy. This figure is significantly higher than the improvement rate of 40% in the patients who had been treated with the conventional therapy. The new therapy was also more effective than the conventional therapy in the treatment of the patients with chronic diseases. The new therapy was more effective than the conventional therapy in the treatment of the patients with chronic diseases. The new therapy was more effective than the conventional therapy in the treatment of the patients with chronic diseases.

the first time in the history of the world, the people of the United States have been compelled to make a choice between two political parties, each of which has a distinct and well-defined platform, and each of which has a definite and well-defined object in view. The people of the United States have been compelled to make a choice between two political parties, each of which has a distinct and well-defined platform, and each of which has a definite and well-defined object in view.

RESULTS
XX
S₂ Sequence 14 AA:
AAK³⁴S³⁵, standard; treated, 194 AA.
XX
AA⁷⁵S⁷⁶
XX
14-Phe³⁴S³⁵ (first edit)
XX
Hybrid human cytokine LIF-E.
XX
Hybrid cytokines: standard PEG-LIF-E, 194 AA;
XX
synthetic,
XX
P1
Key differences between standard and treated:
Miscellaneous
PN
W⁹⁵I⁹⁹A,
XX
P1
in MAY 1995,
XX
P1
67-NV 1994;
XX
18-NV 1994;
XX
HUFC-HUTCHINS CANCERS CENTER, India
XX
P1
Lentiviral vector, 194 AA;
XX
WP¹ 1995 194 AA, /25,
DR
10K
N PEG; AAK³⁴S³⁵,
XX
New hybrid cytokines with alpha² helical vector, obtained from different
P1
sources - also DNA encoding them, vector, etc.; first edit;
P1
used for treating cancer, terminal disease, etc.
XX
claim 14: Date: 33 34: 5249; Finalish.
XX
The cytokine containing genes for leukemia inhibitory factor (LIF),
granulocyte-macrophage stimulating factor (GM-CSF) and cytokine (C),
luteinizing-hormone (LH), only partially overlapping, is treated by the alpha² helical
conformation (C) have been claimed and given a 194 AA sequence. In
the G, L, E, C and D each comprise four amino acid residues. In
each cytokine, the first four amino acids are the same as those in the
alpha helical linker sequence of the other cytokines. The GM-CSF
provides a group of therapeutic hybrid cytokines having a size ranging
from about 10 to about 194 kDa. Each hybrid cytokine contains three
four alpha-helical sequences of linking sequences, a portion of which are
5-40 AA's in length. In the nomenclature of the hybrid cytokines, the
upper case letters designating the alpha helical linking sequences, lower case
letters (whether Arabic numerals or Latin letters) indicate the
a specific linking sequence. The first four alpha helical
sequences of LIF were derived from LIF, at positions 1-4, and the
alpha sequence was derived from LIF, at positions 5-40.

Wed Jan 23 07:27:22 2002

us-09-674-436-1.rag

Page 12

RECEIVED: APRIL 10, 1964
ATTORNEY FOR DEFENDANT:
INFORMATION FOR STG NO. 133,
SEQUENCE CHARACTERISTICS:
LENGTH: 142
TYPE: ANALOGUE
DATE REC'D.: APR 10, 1964
PCN: 11594-1287-19

REVIEW ARTICLE
APPLIED SYSTEMS MODELING FOR
SEQUENCE CHARACTERISTICS:
LENGTH, TYPE, AND
DETECTION. BY J. H. SAWYER

AMERISOURCE, CIVIL Therapeutics, Inc.
STREET: 200 ELLIOTT Avenue West, Suite 400
CITY: Seattle
STATE: Washington
COUNTY: U.S.A.
ZIP: 98109

COMPUTER READABLE FORM:

METHOD TYPE: 3rd Molar, 144RE, 44411, 44412, 44413, 44414
SUBTYPE: ASI 100, Separable,
OPPONENT SYSTEM: MS-100 WORKSTATION
SUSPENDED: Workstation UNKNOWN

CURRENT APPLICATION DATA:

APPLICANT'S NAME: AMERISOURCE, INC.
FILING DATE: 10/23/1995
CLASSIFICATION: 510(1)(A)
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 10849002, 1992
FILING DATE: 12/7/91, 1993
ATTORNEY'S NAME: AMERISOURCE, INC.
NAME: COSTELLO, JEFFREY B. AND PARTRIDGE, ROBERT L.
REGISTRATION NUMBER: 42,581, 431,615, 431,616, 431,617
RELATIONSHIP: PATENT ATTORNEY, ORICNA
TELEPHONE: (206) 822-7100
TELEFAX: (206) 824-6200

INFORMATION FOR THE TRADE NAME:

SEQUENCE: CHARGE OF BUSINESS:
NUMBER: 194
TYPE: animal, actid
PROPRIETY: Linear
MOLECULAR TYPE: Peptide
HYDROLYZED: no
ANTI-SENSE: no
FRAGILE: no
ORIGINAL SOURCE: no
ORGANISM: bovine sapien
DS: 08-149 (10A 13)

卷之三

卷之三

卷之三

THE JOURNAL OF INVESTIGATION

He is a lost soul, I think, and he's got to get out of here.

MICHIGAN NATURE AND LIFE

W. W. WARD, PUBLISHER
THEATRE ARTS MAGAZINE
AUGUST, 1919, \$1.00

THE AMERICAN
PHOTOGRAPHIC
EXHIBITION OF
ART AND INDUSTRY

ALIMENTATION / ACTION / INFORMATION
N° 100 - DÉCEMBRE 1990

卷之三

THE CANADIAN


11. *Leucosia* *leucostoma* *lutea* *luteola*

卷之三

卷之三

• Wed Jan 23 07:27:22 2002

us-09-674-436-1.rai



• M protein = protein in sequence, using 82 model
 • PEST motif = glutamate, leucine, proline, and tyrosine residues
 • Sequence = sequence of protein
 • Selected feature = BLASTM2
 • Searched = 219241 seqs
 • Total number of hits satisfying PEST motif parameter = 219241
 • Maximum DBS seq length = 9
 • Post-processing: Maximum Match 0.8
 • List first 45 summaries
 • Database : PDB_68_PEST
 • 1: first; *
 • 2: pfirst; *
 • 3: pfirst; *
 • 4: pfirst; *

PEST motif is the number of resulting PEST motif containing proteins found in the sequence shorter than or equal to the size of the result, sorted by size, and is derived by analysis of the total size distribution.

8

Result No.	Score	Query	Match Length	DBS
1	25	100.0	116	2
2	25	100.0	148	2
3	25	100.0	156	2
4	25	100.0	165	2
5	25	100.0	172	2
6	25	100.0	186	2
7	25	100.0	186	2
8	25	100.0	193	2
9	25	100.0	197	2
10	25	100.0	202	1
11	25	100.0	203	2
12	25	100.0	209	2
13	25	100.0	244	2
14	25	100.0	249	2
15	25	100.0	252	2
16	25	100.0	273	2
17	25	100.0	292	2
18	25	100.0	410	2
19	25	100.0	438	2
20	25	100.0	446	2
21	25	100.0	447	2
22	25	100.0	494	2
23	25	100.0	531	2
24	25	100.0	596	2
25	25	100.0	416	3
26	25	100.0	435	3
27	25	100.0	436	2
28	25	100.0	436	2
29	25	100.0	446	2

Scanned: 219241 seqs
 Total number of hits satisfying PEST motif parameter = 219241

Maximum DBS seq length = 9
 Post-processing: Maximum Match 0.8
 List first 45 summaries

Database : PDB_68_PEST

1: first; *
 2: pfirst; *
 3: pfirst; *
 4: pfirst; *

SUMMARY

PEST

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

24

卷之三


W. H. DODGE, JR., *Editor*
J. W. BROWN, *Associate Editor*
C. E. COOPER, *Associate Editor*

1. *Introducing the new system*. A new system is introduced, and its features are explained.

1940-1941
1941-1942
1942-1943
1943-1944
1944-1945
1945-1946
1946-1947
1947-1948
1948-1949
1949-1950
1950-1951
1951-1952
1952-1953
1953-1954
1954-1955
1955-1956
1956-1957
1957-1958
1958-1959
1959-1960
1960-1961
1961-1962
1962-1963
1963-1964
1964-1965
1965-1966
1966-1967
1967-1968
1968-1969
1969-1970
1970-1971
1971-1972
1972-1973
1973-1974
1974-1975
1975-1976
1976-1977
1977-1978
1978-1979
1979-1980
1980-1981
1981-1982
1982-1983
1983-1984
1984-1985
1985-1986
1986-1987
1987-1988
1988-1989
1989-1990
1990-1991
1991-1992
1992-1993
1993-1994
1994-1995
1995-1996
1996-1997
1997-1998
1998-1999
1999-2000
2000-2001
2001-2002
2002-2003
2003-2004
2004-2005
2005-2006
2006-2007
2007-2008
2008-2009
2009-2010
2010-2011
2011-2012
2012-2013
2013-2014
2014-2015
2015-2016
2016-2017
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
2024-2025
2025-2026
2026-2027
2027-2028
2028-2029
2029-2030
2030-2031
2031-2032
2032-2033
2033-2034
2034-2035
2035-2036
2036-2037
2037-2038
2038-2039
2039-2040
2040-2041
2041-2042
2042-2043
2043-2044
2044-2045
2045-2046
2046-2047
2047-2048
2048-2049
2049-2050
2050-2051
2051-2052
2052-2053
2053-2054
2054-2055
2055-2056
2056-2057
2057-2058
2058-2059
2059-2060
2060-2061
2061-2062
2062-2063
2063-2064
2064-2065
2065-2066
2066-2067
2067-2068
2068-2069
2069-2070
2070-2071
2071-2072
2072-2073
2073-2074
2074-2075
2075-2076
2076-2077
2077-2078
2078-2079
2079-2080
2080-2081
2081-2082
2082-2083
2083-2084
2084-2085
2085-2086
2086-2087
2087-2088
2088-2089
2089-2090
2090-2091
2091-2092
2092-2093
2093-2094
2094-2095
2095-2096
2096-2097
2097-2098
2098-2099
2099-20100

19. *Leucosia* *leucostoma* *leucostoma* *leucostoma* *leucostoma* *leucostoma*

◆ 中国古典文学名著集成 (卷之三)



1
key 14

1
key 15

1
key 16

1
key 17

1
key 18

1
key 19

1
key 20

1
key 21

1
key 22

1
key 23

1
key 24

1
key 25

1
key 26

1
key 27

1
key 28

1
key 29

1
key 30

1
key 31

1
key 32

1
key 33

1
key 34

1
key 35

1
key 36

1
key 37

1
key 38

1
key 39

1
key 40

1
key 41

1
key 42

1
key 43

1
key 44

1
key 45

1
key 46

1
key 47

1
key 48

1
key 49

1
key 50

1
key 51

1
key 52

1
key 53

1
key 54

1
key 55

1
key 56

1
key 57

1
key 58

1
key 59

1
key 60

1
key 61

1
key 62

1
key 63

1
key 64

1
key 65

1
key 66

1
key 67

1
key 68

1
key 69

1
key 70

1
key 71

1
key 72

1
key 73

1
key 74

1
key 75

1
key 76

1
key 77

1
key 78

1
key 79

1
key 80

1
key 81

1
key 82

1
key 83

1
key 84

1
key 85

1
key 86

1
key 87

1
key 88

1
key 89

1
key 90

1
key 91

1
key 92

1
key 93

1
key 94

1
key 95

1
key 96

1
key 97

1
key 98

1
key 99

1
key 100

1
key 101

1
key 102

1
key 103

1
key 104

1
key 105

1
key 106

1
key 107

1
key 108

1
key 109

1
key 110

1
key 111

1
key 112

1
key 113

1
key 114

1
key 115

1
key 116

1
key 117

1
key 118

1
key 119

1
key 120

1
key 121

1
key 122

1
key 123

1
key 124

1
key 125

1
key 126

1
key 127

1
key 128

1
key 129

1
key 130

1
key 131

1
key 132

1
key 133

1
key 134

1
key 135

1
key 136

1
key 137

1
key 138

1
key 139

1
key 140

1
key 141

1
key 142

1
key 143

1
key 144

1
key 145

1
key 146

1
key 147

1
key 148

1
key 149

1
key 150

1
key 151

1
key 152

1
key 153

1
key 154

1
key 155

1
key 156

1
key 157

1
key 158

1
key 159

1
key 160

1
key 161

1
key 162

1
key 163

1
key 164

1
key 165

1
key 166

1
key 167

1
key 168

1
key 169

1
key 170

1
key 171

1
key 172

1
key 173

1
key 174

1
key 175

1
key 176

1
key 177

1
key 178

1
key 179

1
key 180

1
key 181

1
key 182

1
key 183

1
key 184

1
key 185

1
key 186

1
key 187

1
key 188

1
key 189

1
key 190

1
key 191

1
key 192

1
key 193

1
key 194

1
key 195

1
key 196

1
key 197

1
key 198

1
key 199

1
key 200

1
key 201

1
key 202

1
key 203

1
key 204

1
key 205

1
key 206

1
key 207

1
key 208

1
key 209

1
key 210

1
key 211

1
key 212

1
key 213

1
key 214

1
key 215

1
key 216

1
key 217

1
key 218

1
key 219

1
key 220

1
key 221

1
key 222

1
key 223

1
key 224

1
key 225

1
key 226

1
key 227

1
key 228

1
key 229

1
key 230

1
key 231

1
key 232

1
key 233

1
key 234

1
key 235

1
key 236

1
key 237

1
key 238

1
key 239

1
key 240

1
key 241

1
key 242

1
key 243

1
key 244

1
key 245

1
key 246

1
key 247

1
key 248

1
key 249

1
key 250

1
key 251

1
key 252

1
key 253

1
key 254

1
key 255

1
key 256

1
key 257

1
key 258

1
key 259

1
key 260

1
key 261

1
key 262

1
key 263

1
key 264

1
key 265

1
key 266

1
key 267

1
key 268

1
key 269

1
key 270

1
key 271

1
key 272

1
key 273

1
key 274

1
key 275

1
key 276

1
key 277

1
key 278

1
key 279

1
key 280

1
key 281

1
key 282

1
key 283

1
key 284

1
key 285

information on further
development of the
situation.

REVIEW OF INFORMATION

The information available
on the situation in
Kosovo is as follows:

ARMED GROUPS

There are two main
armed groups operating
in Kosovo: the
Kosovo Liberation Army
(KLA) and the
Army of the
Vojvodina Serbs (AVS).

KOSOVO LIBERATION ARMY (KLA)

The KLA is an
Armenian-dominated
group that has been
operating in Kosovo
since 1991. It is
estimated that the
KLA has between
10,000 and 15,000
members, mostly
from the Albanian
population.

ARMY OF THE VOJVODINA SERBS (AVS)

The AVS is a
Serbian-dominated
group that has been
operating in Kosovo
since 1991. It is
estimated that the
AVS has between
5,000 and 10,000
members, mostly
from the Serbian
population.

REFUGEE SITUATION

There are approximately
1.5 million refugees
in Kosovo, mostly
from the Albanian
population. The
refugee situation
is particularly
acute in the
northern part of
the country, where
many people have
been displaced
from their homes
by the conflict.

ECONOMIC SITUATION

The economy in
Kosovo is still
recovering from
the conflict. The
country is heavily
dependent on
international
aid and has a
high rate of
unemployment.

GOVERNMENT AND POLITICAL PARTIES

The government
of Kosovo is
still in the
process of
being formed.
The main political
parties are the
Democratic
Party of Kosovo
(DKP), the
Socialist Party
(SP), and the
Independent
Democratic
Party (IDP).

RELATIONS WITH NEIGHBORING COUNTRIES

Relations with
neighboring
countries are
generally
good, although
there are some
disputes over
border issues.

ENVIRONMENTAL SITUATION

The environment
in Kosovo is
under
considerable
stress due to
industrial
activity and
deforestation.

EDUCATION AND HEALTH CARE

Education and
health care
systems are
under
strain due to
the conflict.

ARTICLE 19 REPORT

Article 19 is a
non-governmental
organization that
works to
protect
human rights
and freedom
of expression.
It has
published
several
reports
on the
situation
in Kosovo.

REFUGEE SITUATION

The refugee
situation
is a
major
concern
in Kosovo.
The
government
is trying
to
find
ways
to
improve
the
situation
for
refugees.

ECONOMIC SITUATION

The economy
in Kosovo
is still
recovering
from
the
conflict.
The
country
is
heavily
dependent
on
international
aid and
has
a
high
rate
of
unemployment.

GOVERNMENT AND POLITICAL PARTIES

The government
of Kosovo
is still
in
the
process
of
being
formed.
The
main
political
parties
are
the
Democratic
Party
of
Kosovo
(DKP),
the
Socialist
Party
(SP),
and
the
Independent
Democratic
Party
(IDP).

RELATIONS WITH NEIGHBORING COUNTRIES

Relations
with
neighboring
countries
are
generally
good,
although
there
are
some
disputes
over
border
issues.

ENVIRONMENTAL SITUATION

The
environment
in
Kosovo
is
under
considerable
stress
due
to
industrial
activity
and
deforestation.

EDUCATION AND HEALTH CARE

Education
and
health
care
systems
are
under
strain
due
to
the
conflict.

ARTICLE 19 REPORT

Article 19
is a
non-
governmental
organization
that
works
to
protect
human
rights
and
freedom
of
expression.
It
has
published
several
reports
on
the
situation
in
Kosovo.

and the first in the HE. The second was a standard monolithic microstrip antenna, and the third was a modified version of the MILAN-3B. All three were mounted on a printed circuit board and connected to a 50 ohm coaxial cable. The cables were terminated with SMA connectors. The cables were terminated with SMA connectors.

The WLLS system consists of a base station, a repeater, and two mobile stations. The base station is located at the top of a hill, and the repeater is located in the middle of a valley. The two mobile stations are located in the bottom of the valley. The base station transmits a signal to the repeater, which then transmits it to the two mobile stations. The mobile stations receive the signal from the repeater and then transmit it back to the base station. The base station also receives signals from the two mobile stations.

The WLLS system has a range of approximately 10 km. The base station has a power output of 100 mW, and the repeater has a power output of 50 mW. The two mobile stations have a power output of 10 mW each. The base station has a transmission frequency of 900 MHz, and the repeater has a transmission frequency of 850 MHz. The two mobile stations have a transmission frequency of 850 MHz.

The WLLS system has a range of approximately 10 km. The base station has a power output of 100 mW, and the repeater has a power output of 50 mW. The two mobile stations have a power output of 10 mW each. The base station has a transmission frequency of 900 MHz, and the repeater has a transmission frequency of 850 MHz. The two mobile stations have a transmission frequency of 850 MHz.

The WLLS system has a range of approximately 10 km. The base station has a power output of 100 mW, and the repeater has a power output of 50 mW. The two mobile stations have a power output of 10 mW each. The base station has a transmission frequency of 900 MHz, and the repeater has a transmission frequency of 850 MHz. The two mobile stations have a transmission frequency of 850 MHz.

The WLLS system has a range of approximately 10 km. The base station has a power output of 100 mW, and the repeater has a power output of 50 mW. The two mobile stations have a power output of 10 mW each. The base station has a transmission frequency of 900 MHz, and the repeater has a transmission frequency of 850 MHz. The two mobile stations have a transmission frequency of 850 MHz.

The WLLS system has a range of approximately 10 km. The base station has a power output of 100 mW, and the repeater has a power output of 50 mW. The two mobile stations have a power output of 10 mW each. The base station has a transmission frequency of 900 MHz, and the repeater has a transmission frequency of 850 MHz. The two mobile stations have a transmission frequency of 850 MHz.

The WLLS system has a range of approximately 10 km. The base station has a power output of 100 mW, and the repeater has a power output of 50 mW. The two mobile stations have a power output of 10 mW each. The base station has a transmission frequency of 900 MHz, and the repeater has a transmission frequency of 850 MHz. The two mobile stations have a transmission frequency of 850 MHz.

The WLLS system has a range of approximately 10 km. The base station has a power output of 100 mW, and the repeater has a power output of 50 mW. The two mobile stations have a power output of 10 mW each. The base station has a transmission frequency of 900 MHz, and the repeater has a transmission frequency of 850 MHz. The two mobile stations have a transmission frequency of 850 MHz.

OR SMART: SMD0248 ANK_1

OR PROSHIE: PSYCHOB: ANK_REPEAT: 5

OR PROSHIE: PSYCHOB: ANK_REPEAT: 5

OR PROSHIE: PSYCHOB: ANK_REPEAT: 5

KW Nuclear protein, Transcription regulator, ANK domain, Phosphotyrosine

FT DOMAIN_1 112 PRO_RCHL

FT REPEAT 124 ANK_1

FT REPEAT 163 ANK_2

FT REPEAT 166 ANK_3

FT REPEAT 237 ANK_4

FT REPEAT 239 ANK_5

FT REPEAT 262 ANK_6

FT REPEAT 301 ANK_7

FT REPEAT 323 ANK_8

FT REPEAT 350 ANK_9

FT REPEAT 376 ANK_10

FT REPEAT 405 ANK_11

FT REPEAT 432 ANK_12

FT REPEAT 459 ANK_13

FT REPEAT 486 ANK_14

FT REPEAT 513 ANK_15

FT REPEAT 540 ANK_16

FT REPEAT 567 ANK_17

FT REPEAT 594 ANK_18

FT REPEAT 621 ANK_19

FT REPEAT 648 ANK_20

FT REPEAT 675 ANK_21

FT REPEAT 702 ANK_22

FT REPEAT 729 ANK_23

FT REPEAT 756 ANK_24

FT REPEAT 783 ANK_25

FT REPEAT 810 ANK_26

FT REPEAT 837 ANK_27

FT REPEAT 864 ANK_28

FT REPEAT 891 ANK_29

FT REPEAT 918 ANK_30

FT REPEAT 945 ANK_31

FT REPEAT 972 ANK_32

FT REPEAT 1000 ANK_33

FT REPEAT 1027 ANK_34

FT REPEAT 1054 ANK_35

FT REPEAT 1081 ANK_36

FT REPEAT 1108 ANK_37

FT REPEAT 1135 ANK_38

FT REPEAT 1162 ANK_39

FT REPEAT 1189 ANK_40

FT REPEAT 1216 ANK_41

FT REPEAT 1243 ANK_42

FT REPEAT 1270 ANK_43

FT REPEAT 1297 ANK_44

FT REPEAT 1324 ANK_45

FT REPEAT 1351 ANK_46

FT REPEAT 1378 ANK_47

FT REPEAT 1405 ANK_48

FT REPEAT 1432 ANK_49

FT REPEAT 1459 ANK_50

FT REPEAT 1486 ANK_51

FT REPEAT 1513 ANK_52

FT REPEAT 1540 ANK_53

FT REPEAT 1567 ANK_54

FT REPEAT 1594 ANK_55

FT REPEAT 1621 ANK_56

FT REPEAT 1648 ANK_57

FT REPEAT 1675 ANK_58

FT REPEAT 1702 ANK_59

FT REPEAT 1729 ANK_60

FT REPEAT 1756 ANK_61

FT REPEAT 1783 ANK_62

FT REPEAT 1810 ANK_63

FT REPEAT 1837 ANK_64

FT REPEAT 1864 ANK_65

FT REPEAT 1891 ANK_66

FT REPEAT 1918 ANK_67

FT REPEAT 1945 ANK_68

FT REPEAT 1972 ANK_69

FT REPEAT 2000 ANK_70

FT REPEAT 2027 ANK_71

FT REPEAT 2054 ANK_72

FT REPEAT 2081 ANK_73

FT REPEAT 2108 ANK_74

FT REPEAT 2135 ANK_75

FT REPEAT 2162 ANK_76

FT REPEAT 2189 ANK_77

FT REPEAT 2216 ANK_78

FT REPEAT 2243 ANK_79

FT REPEAT 2270 ANK_80

FT REPEAT 2297 ANK_81

FT REPEAT 2324 ANK_82

FT REPEAT 2351 ANK_83

FT REPEAT 2378 ANK_84

FT REPEAT 2405 ANK_85

FT REPEAT 2432 ANK_86

FT REPEAT 2459 ANK_87

FT REPEAT 2486 ANK_88

FT REPEAT 2513 ANK_89

FT REPEAT 2540 ANK_90

FT REPEAT 2567 ANK_91

FT REPEAT 2594 ANK_92

FT REPEAT 2621 ANK_93

FT REPEAT 2648 ANK_94

FT REPEAT 2675 ANK_95

FT REPEAT 2702 ANK_96

FT REPEAT 2729 ANK_97

FT REPEAT 2756 ANK_98

FT REPEAT 2783 ANK_99

FT REPEAT 2810 ANK_100

FT REPEAT 2837 ANK_101

FT REPEAT 2864 ANK_102

FT REPEAT 2891 ANK_103

FT REPEAT 2918 ANK_104

FT REPEAT 2945 ANK_105

FT REPEAT 2972 ANK_106

FT REPEAT 3000 ANK_107

FT REPEAT 3027 ANK_108

FT REPEAT 3054 ANK_109

FT REPEAT 3081 ANK_110

FT REPEAT 3108 ANK_111

FT REPEAT 3135 ANK_112

FT REPEAT 3162 ANK_113

FT REPEAT 3189 ANK_114

FT REPEAT 3216 ANK_115

FT REPEAT 3243 ANK_116

FT REPEAT 3270 ANK_117

FT REPEAT 3297 ANK_118

FT REPEAT 3324 ANK_119

FT REPEAT 3351 ANK_120

FT REPEAT 3378 ANK_121

FT REPEAT 3405 ANK_122

FT REPEAT 3432 ANK_123

FT REPEAT 3459 ANK_124

FT REPEAT 3486 ANK_125

FT REPEAT 3513 ANK_126

FT REPEAT 3540 ANK_127

FT REPEAT 3567 ANK_128

FT REPEAT 3594 ANK_129

FT REPEAT 3621 ANK_130

FT REPEAT 3648 ANK_131

FT REPEAT 3675 ANK_132

FT REPEAT 3702 ANK_133

FT REPEAT 3729 ANK_134

FT REPEAT 3756 ANK_135

FT REPEAT 3783 ANK_136

FT REPEAT 3810 ANK_137

FT REPEAT 3837 ANK_138

FT REPEAT 3864 ANK_139

FT REPEAT 3891 ANK_140

FT REPEAT 3918 ANK_141

FT REPEAT 3945 ANK_142

FT REPEAT 3972 ANK_143

FT REPEAT 4000 ANK_144

FT REPEAT 4027 ANK_145

FT REPEAT 4054 ANK_146

FT REPEAT 4081 ANK_147

FT REPEAT 4108 ANK_148

FT REPEAT 4135 ANK_149

FT REPEAT 4162 ANK_150

FT REPEAT 4189 ANK_151

FT REPEAT 4216 ANK_152

FT REPEAT 4243 ANK_153

FT REPEAT 4270 ANK_154

FT REPEAT 4297 ANK_155

FT REPEAT 4324 ANK_156

FT REPEAT 4351 ANK_157

FT REPEAT 4378 ANK_158

FT REPEAT 4405 ANK_159

FT REPEAT 4432 ANK_160

FT REPEAT 4459 ANK_161

FT REPEAT 4486 ANK_162

FT REPEAT 4513 ANK_163

FT REPEAT 4540 ANK_164

FT REPEAT 4567 ANK_165

FT REPEAT 4594 ANK_166

FT REPEAT 4621 ANK_167

FT REPEAT 4648 ANK_168

FT REPEAT 4675 ANK_169

FT REPEAT 4702 ANK_170

FT REPEAT 4729 ANK_171

FT REPEAT 4756 ANK_172

FT REPEAT 4783 ANK_173

FT REPEAT 4810 ANK_174

FT REPEAT 4837 ANK_175

FT REPEAT 4864 ANK_176

FT REPEAT 4891 ANK_177

FT REPEAT 4918 ANK_178

FT REPEAT 4945 ANK_179

FT REPEAT 4972 ANK_180

FT REPEAT 5000 ANK_181

FT REPEAT 5027 ANK_182

FT REPEAT 5054 ANK_183

FT REPEAT 5081 ANK_184

FT REPEAT 5108 ANK_185

FT REPEAT 5135 ANK_186

FT REPEAT 5162 ANK_187

FT REPEAT 5189 ANK_188

FT REPEAT 5216 ANK_189

FT REPEAT 5243 ANK_190

FT REPEAT 5270 ANK_191

FT REPEAT 5297 ANK_192

FT REPEAT 5324 ANK_193

FT REPEAT 5351 ANK_194

FT REPEAT 5378 ANK_195

FT REPEAT 5405 ANK_196

FT REPEAT 5432 ANK_197

FT REPEAT 5459 ANK_198

FT REPEAT 5486 ANK_199

FT REPEAT 5513 ANK_200

FT REPEAT 5540 ANK_201

FT REPEAT 5567 ANK_202

FT REPEAT 5594 ANK_203

FT REPEAT 5621 ANK_204

FT REPEAT 5648 ANK_205

FT REPEAT 5675 ANK_206

FT REPEAT 5702 ANK_207

FT REPEAT 5729 ANK_208

FT REPEAT 5756 ANK_209

FT REPEAT 5783 ANK_210

FT REPEAT 5810 ANK_211

FT REPEAT 5837 ANK_212

FT REPEAT 5864 ANK_213

FT REPEAT 5891 ANK_214

FT REPEAT 5918 ANK_215

FT REPEAT 5945 ANK_216

FT REPEAT 5972 ANK_217

FT REPEAT 6000 ANK_218

FT REPEAT 6027 ANK_219

FT REPEAT 6054 ANK_220

FT REPEAT 6081 ANK_221

FT REPEAT 6108 ANK_222

FT REPEAT 6135 ANK_223

FT REPEAT 6162 ANK_224

FT REPEAT 6189 ANK_225

FT REPEAT 6216 ANK_226

FT REPEAT 6243 ANK_227

FT REPEAT 6270 ANK_228

FT REPEAT 6297 ANK_229

FT REPEAT 6324 ANK_230

FT REPEAT 6351 ANK_231

FT REPEAT 6378 ANK_232

FT REPEAT 6405 ANK_233

FT REPEAT 6432 ANK_234

FT REPEAT 6459 ANK_235

FT REPEAT 6486 ANK_236

FT REPEAT 6513 ANK_237

FT REPEAT 6540 ANK_238

FT REPEAT 6567 ANK_239

FT REPEAT 6594 ANK_240

FT REPEAT 6621 ANK_241

FT REPEAT 6648 ANK_242

FT REPEAT 6675 ANK_243

FT REPEAT 6702 ANK_244

FT REPEAT 6729 ANK_245

FT REPEAT 6756 ANK_246

FT REPEAT 6783 ANK_247

FT REPEAT 6810 ANK_248

FT REPEAT 6837 ANK_249

FT REPEAT 6864 ANK_250

FT REPEAT 6891 ANK_251

FT REPEAT 6918 ANK_252

FT REPEAT 6945 ANK_253

FT REPEAT 6972 ANK_254

FT REPEAT 7000 ANK_255

FT REPEAT 7027 ANK_256

FT REPEAT 7054 ANK_257

FT REPEAT 7081 ANK_258

FT REPEAT 7108 ANK_259

FT REPEAT 7135 ANK_260

FT REPEAT 7162 ANK_261

FT REPEAT 7189 ANK_262

FT REPEAT 7216 ANK_263

FT REPEAT 7243 ANK_264

FT REPEAT 7270 ANK_265

FT REPEAT 7297 ANK_266

FT REPEAT 7324 ANK_267

FT REPEAT 7351 ANK_268

FT REPEAT 7378 ANK_269

FT REPEAT 7405 ANK_270

FT REPEAT 7432 ANK_271

FT REPEAT 7459 ANK_272

FT REPEAT 7486 ANK_273

FT REPEAT 7513 ANK_274

FT REPEAT 7540 ANK_275

FT REPEAT 7567 ANK_276

FT REPEAT 7594 ANK_277

FT REPEAT 7621 ANK_278

FT REPEAT 7648 ANK_279

FT REPEAT 7675 ANK_280

FT REPEAT 7702 ANK_281

FT REPEAT 7729 ANK_282

FT REPEAT 7756 ANK_283

FT REPEAT 7783 ANK_284

FT REPEAT 7810 ANK_285

FT REPEAT 7837 ANK_286

FT REPEAT 7864 ANK_287

FT REPEAT 7891 ANK_288

FT REPEAT 7918 ANK_289

FT REPEAT 7945 ANK_290

FT REPEAT 7972 ANK_291

FT REPEAT 8000 ANK_292

FT REPEAT 8027 ANK_293

FT REPEAT 8054 ANK_294

FT REPEAT 8081 ANK_295

FT REPEAT 8108 ANK_296

FT REPEAT 8135 ANK_297

FT REPEAT 8162 ANK_298

FT REPEAT 8189 ANK_299

FT REPEAT 8216 ANK_300

FT REPEAT 8243 ANK_301

FT REPEAT 8270 ANK_302

FT REPEAT 8297 ANK_303

FT REPEAT 8324 ANK_304

FT REPEAT 8351 ANK_305

FT REPEAT 8378 ANK_306

FT REPEAT 8405 ANK_307

FT REPEAT 8432 ANK_308

FT REPEAT 8459 ANK_309

FT REPEAT 8486 ANK_310

FT REPEAT 8513 ANK_311

FT REPEAT 8540 ANK_312

FT REPEAT 8567 ANK_313

FT REPEAT 8594 ANK_314

FT REPEAT 8621 ANK_315

FT REPEAT 8648 ANK_316

FT REPEAT 8675 ANK_317

FT REPEAT 8702 ANK_318

FT REPEAT 8729 ANK_319

FT REPEAT 8756 ANK_320

FT REPEAT 8783 ANK_321

FT REPEAT 8810 ANK_322

FT REPEAT 8837 ANK_323

FT REPEAT 8864 ANK_324

FT REPEAT 8891 ANK_325

FT REPEAT 8918 ANK_326

FT REPEAT 8945 ANK_327

FT REPEAT 8972 ANK_328

FT REPEAT 9000 ANK_329

FT REPEAT 9027 ANK_330

FT REPEAT 9054 ANK_331

FT REPEAT 9081 ANK_332

FT REPEAT 9108 ANK_333

FT REPEAT 9135 ANK_334

FT REPEAT 9162 ANK_335

FT REPEAT 9189 ANK_336

FT REPEAT 9216 ANK_337

FT REPEAT 9243 ANK_338

FT REPEAT 9270 ANK_339

FT REPEAT 9297 ANK_340

FT REPEAT 9324 ANK_341

FT REPEAT 9351 ANK_342

FT REPEAT 9378 ANK_343

FT REPEAT 9405 ANK_344

FT REPEAT 9432 ANK_345

FT REPEAT 9459 ANK_346

FT REPEAT 9486 ANK_347

FT REPEAT 9513 ANK_348

FT REPEAT 9540 ANK_349

FT REPEAT 9567 ANK_350

FT REPEAT 9594 ANK_351

FT REPEAT 9621 ANK_352

FT REPEAT 9648 ANK_353

FT REPEAT 9675 ANK_354

FT REPEAT 9702 ANK_355

FT REPEAT 9729 ANK_356

FT REPEAT 9756 ANK_357

FT REPEAT 9783 ANK_358

FT REPEAT 9810 ANK_359

FT REPEAT 9837 ANK_360

FT REPEAT 9864 ANK_361

FT REPEAT 9891 ANK_362

FT REPEAT 9918 ANK_363

FT REPEAT 9945 ANK_364

FT REPEAT 9972 ANK_365

FT REPEAT 10000 ANK_366

FT REPEAT 10027 ANK_367

FT REPEAT 10054 ANK_368

FT REPEAT 10081 ANK_369

FT REPEAT 10108 ANK_370

FT REPEAT 10135 ANK_371

FT REPEAT 10162 ANK_372

FT REPEAT 10189 ANK_373

FT REPEAT 10216 ANK_374

FT REPEAT 10243 ANK_375

FT REPEAT 10270 ANK_376

FT REPEAT 10297 ANK_377

FT REPEAT 10324 ANK_378

FT REPEAT 10351 ANK_379

FT REPEAT 10378 ANK_380

FT REPEAT 10405 ANK_381

FT REPEAT 10432 ANK_382

FT REPEAT 10459 ANK_383

FT REPEAT 10486 ANK_384

FT REPEAT 10513 ANK_385

FT REPEAT 10540 ANK_386

FT REPEAT 10567 ANK_387

FT REPEAT 10594 ANK_388

FT REPEAT 10621 ANK_389

FT REPEAT 10648 ANK_390

FT REPEAT 10675 ANK_391

FT REPEAT 10702 ANK_392

FT REPEAT 10729 ANK_393

FT REPEAT 10756 ANK_394

FT REPEAT 10783 ANK_395

FT REPEAT 10810 ANK_396

FT REPEAT 10837 ANK_397

FT REPEAT 10864 ANK_398

FT REPEAT 10891 ANK_399

FT REPEAT 10918 ANK_400

FT REPEAT 10945 ANK_401

FT REPEAT 10972 ANK_402

FT REPEAT 11000 ANK_403

FT REPEAT 11027 ANK_404

FT REPEAT 11054 ANK_405

FT REPEAT 11081 ANK_406

FT REPEAT 11108 ANK_407

FT REPEAT 11135 ANK_408

FT REPEAT 11162 ANK_409

FT REPEAT 11189 ANK_410

FT REPEAT 11216 ANK_411

FT REPEAT 11243 ANK_412

FT REPEAT 11270 ANK_413

FT REPEAT 11297 ANK_414

FT REPEAT 11324 ANK_415

FT REPEAT 11351 ANK_416

FT REPEAT 11378 ANK_417

FT REPEAT 11405 ANK_418

FT REPEAT 11432 ANK_419

FT REPEAT 11459 ANK_420

FT REPEAT 11486 ANK_421

FT REPEAT 11513 ANK_422

FT REPEAT 11540 ANK_423

FT REPEAT 11567 ANK_424

FT REPEAT 11594 ANK_425

FT REPEAT 11621 ANK_426

FT REPEAT 11648 ANK_427

FT REPEAT 11675 ANK_428

FT REPEAT 11702 ANK_429

FT REPEAT 11729 ANK_430

FT REPEAT 11756 ANK_431

FT REPEAT 11783 ANK_432

FT REPEAT 11810 ANK_433

FT REPEAT 11837 ANK_434

FT REPEAT 11864 ANK_435

FT REPEAT 11891 ANK_436

FT REPEAT 11918 ANK_437

FT REPEAT 11945 ANK_438

FT REPEAT 11972 ANK_439

FT REPEAT 12000 ANK_440

FT REPEAT 12027 ANK_441

FT REPEAT 12054 ANK_442

FT REPEAT 12081 ANK_443

FT REPEAT 12108 ANK_444

FT REPEAT 12135 ANK_445

FT REPEAT 12162 ANK_446

FT REPEAT 12189 ANK_447

FT REPEAT 12216 ANK_448

FT REPEAT 12243 ANK_449

FT REPEAT 12270 ANK_450

FT REPEAT 12297 ANK_451

FT REPEAT 12324 ANK_452

FT REPEAT 12351 ANK_453

FT REPEAT 12378 ANK_454

FT REPEAT 12405 ANK_455

FT REPEAT 12432 ANK_456

FT REPEAT 12459 ANK_457

FT REPEAT 12486 ANK_458

FT REPEAT 12513 ANK_459

FT REPEAT 12540 ANK_460

FT REPEAT 12567 ANK_461

FT REPEAT 12594 ANK_462

FT REPEAT 12621 ANK_463

FT REPEAT 12648 ANK_464

FT REPEAT 12675 ANK_465

FT REPEAT 12702 ANK_466

FT REPEAT 12729 ANK_467

FT REPEAT 12756 ANK_468

FT REPEAT 12783 ANK_469

FT REPEAT 12810 ANK_470

FT REPEAT 12837 ANK_471

FT REPEAT 12864 ANK_472

FT REPEAT 12891 ANK_473

FT REPEAT 12918 ANK_474

FT REPEAT 12945 ANK_475

FT REPEAT 12972 ANK_476

FT REPEAT 13000 ANK_477

FT REPEAT 13027 ANK_478

FT REPEAT 13054 ANK_479

FT REPEAT 13081 ANK_480

FT REPEAT 13108 ANK_481

FT REPEAT 13135 ANK_482

FT REPEAT 13162 ANK_483

FT REPEAT 13189 ANK_484

FT REPEAT 13216 ANK_485

FT REPEAT 13243 ANK_486

FT REPEAT 13270 ANK_487

FT REPEAT 13297 ANK_488

FT REPEAT 13324 ANK_489

FT REPEAT 13351 ANK_490

FT REPEAT 13378 ANK_491

FT REPEAT 13405 ANK_492

FT REPEAT 13432 ANK_493

FT REPEAT 13459 ANK_494

FT REPEAT 13486 ANK_495

FT REPEAT 13513 ANK_496

FT REPEAT 13540 ANK_497

FT REPEAT 13567 ANK_498

FT REPEAT 13594 ANK_499

FT REPEAT 13621 ANK_500

FT REPEAT 13648 ANK_501

FT REPEAT 13675 ANK_502

FT REPEAT 13702 ANK_503

FT REPEAT 13729 ANK_504

FT REPEAT 13756 ANK_505

FT REPEAT 13783 ANK_506

FT REPEAT 13810 ANK_507

FT REPEAT 13837 ANK_508

FT REPEAT 13864 ANK_509

FT REPEAT 13891 ANK_510

FT REPEAT 13918 ANK_511

FT REPEAT 13945 ANK_512

FT REPEAT 13972 ANK_513

FT REPEAT 14000 ANK_514

FT REPEAT 14027 ANK_515

FT REPEAT 14054 ANK_516

FT REPEAT 14081 ANK_517

FT REPEAT 14108 ANK_518

FT REPEAT 14135 ANK_519

FT REPEAT 14162 ANK_520

FT REPEAT 14189 ANK_521

FT REPEAT 14216 ANK_522

FT REPEAT 14243 ANK_523

FT REPEAT 14270 ANK_524

FT REPEAT 14297 ANK_525

FT REPEAT 14324 ANK_526

FT REPEAT 14351 ANK_527

FT REPEAT 14378 ANK_528

FT REPEAT 14405 ANK_529

FT REPEAT 14432 ANK_530

FT REPEAT 14459 ANK_531

FT REPEAT 14486 ANK_532

FT REPEAT 14513 ANK_533

FT REPEAT 14540 ANK_534

FT REPEAT 14567 ANK_535

FT REPEAT 14594 ANK_536

FT REPEAT 14621 ANK_537

FT REPEAT 14648 ANK_538

FT REPEAT 14675 ANK_539

FT REPEAT 14702 ANK_540

FT REPEAT 14729 ANK_541

FT REPEAT 14756 ANK_542

FT REPEAT 14783 ANK_543

FT REPEAT 14810 ANK_544

FT REPEAT 14837 ANK_545

FT REPEAT 14864 ANK_546

FT REPEAT 14891 ANK_547

FT REPEAT 14918 ANK_548

FT REPEAT 14945 ANK_549

FT REPEAT 14972 ANK_550

FT REPEAT 15000 ANK_551

FT REPEAT 15027 ANK_552

FT REPEAT 15054 ANK_553

FT REPEAT 15081 ANK_554

FT REPEAT 15108 ANK_555

FT REPEAT 15135 ANK_556

FT REPEAT 15162 ANK_557

FT REPEAT 15189 ANK_558

FT REPEAT 15216 ANK_559

FT REPEAT 15243 ANK_560

FT REPEAT 15270 ANK_561

FT REPEAT 15297 ANK_562

FT REPEAT 15324 ANK_563

FT REPEAT 15351 ANK_564

FT REPEAT 15378 ANK_565

FT REPEAT 15405 ANK_566

FT REPEAT 15432 ANK_567

FT REPEAT 15459 ANK_568

FT REPEAT 15486 ANK_569

FT REPEAT 15513 ANK_570

FT REPEAT 15540 ANK_571

FT REPEAT 15567 ANK_572

FT REPEAT 15594 ANK_573

FT REPEAT 15621 ANK_574

FT REPEAT 15648 ANK_575

FT REPEAT 15675 ANK_576

FT REPEAT 15702 ANK_577

FT REPEAT 15729 ANK_578

FT REPEAT 15756 ANK_579

FT REPEAT 15783 ANK_580

FT REPEAT 15810 ANK_581

FT REPEAT 15837 ANK_582

FT REPEAT 15864 ANK_583

FT REPEAT 15891 ANK_584

FT REPEAT 15918 ANK_585

FT REPEAT 15945 ANK_586

FT REPEAT 15972 ANK_587

FT REPEAT 16000 ANK_588

FT REPEAT 16027 ANK_589

FT REPEAT 16054 ANK_590

FT REPEAT 16081 ANK_591

FT REPEAT 16108 ANK_592

FT REPEAT 16135 ANK_593

FT REPEAT 16162 ANK_594

FT REPEAT 16189 ANK_595

FT REPEAT 16216 ANK_596

FT REPEAT 16243 ANK_597

FT REPEAT 16270 ANK_598

FT REPEAT 16297 ANK_599

FT REPEAT 16324 ANK_600

FT REPEAT 16351 ANK_601

FT REPEAT 16378 ANK_602

FT REPEAT 16405 ANK_603

FT REPEAT 16432 ANK_604

FT REPEAT 16459 ANK_605

FT REPEAT 16486 ANK_606

FT REPEAT 16513 ANK_607

FT REPEAT 16540 ANK_608

FT REPEAT 16567 ANK_609

FT REPEAT 16594 ANK_610

FT REPEAT 16621 ANK_611

FT REPEAT 16648 ANK_612

FT REPEAT 16675 ANK_613

FT REPEAT 16702 ANK_614

FT REPEAT 16729 ANK_615

FT REPEAT 16756 ANK_616

FT REPEAT 16783 ANK_617

FT REPEAT 16810 ANK_618

FT REPEAT 16837 ANK_619

FT REPEAT 16864 ANK_620

FT REPEAT 16891 ANK_621

FT REPEAT 16918 ANK_622

FT REPEAT 16945 ANK_623

FT REPEAT 16972 ANK_624

FT REPEAT 17000 ANK_625

FT REPEAT 17027 ANK_626

FT REPEAT 17054 ANK_627

FT REPEAT 17081 ANK_628

FT REPEAT 17108 ANK_629

FT REPEAT 17135 ANK_630

FT REPEAT 17162 ANK_631

FT REPEAT 17189 ANK_632

FT REPEAT 17216 ANK_633

FT REPEAT 17243 ANK_634

FT REPEAT 17270 ANK_635

FT REPEAT 17297 ANK_636

FT REPEAT 17324 ANK_637

McGraw-Hill, New York, 1962. A. L. Lewis, *Principles of Economics*, McGraw-Hill, New York, 1962.

Yes, said John, I am a good boy.

Copyright (c) 1993 CambridgeSoft. All rights reserved.

4 protein
protein search, using SW model
run on:

the:
correct score: 0.5-0.674-4.395
sequence: 101HIG6
scoring table: Blosum62
database: Gapped 10.0 + Gapwidth 0.5
matched: 47335 30436 14627 2229 13851
actual number of hits satisfying chosen parameters:
minimum DB seq length: 10
maximum DB seq length: 2030000000

POST-PROCESSING: Minimum Match: 0.8
Maximum Match: 1.004
List first 45 summaries

1: SP_RBMEL_17; *
2: SP_barberry13; *
3: SP_tunagi; *
4: SP_humuli; *
5: SP_invertibrata; *
6: SP_mammal; *
7: SP_bifer; *
8: SP_cannabis; *
9: SP_diphysa; *
10: SP_plant; *
11: SP_teplant; *
12: SP_gibbons; *
13: SP_wrebeliae; *
14: SP_merriamii; *

Pred. No. is the number of results per database entry, i.e. the number of results for a given query sequence greater than or equal to the score. The result is sorted by pred. no. and is derived by analogy of the test database. The following table summarizes the results.

Query	Match	length	DB	pred. no.
SP_barberry13	116	2	Q92AF5	1
SP_tunagi	140	2	Q92AF6	2
SP_humuli	141	1	Q92AF7	3
SP_invertibrata	141	1	Q92AF8	4
SP_mammal	141	1	Q92AF9	5
SP_bifer	148	2	Q92AFK	6
SP_cannabis	153	3	Q92AFR	7
SP_diphysa	160	2	Q92AFS	8
SP_plant	169	10	Q92AFM	9
SP_teplant	169	10	Q92AFN	10
SP_gibbons	172	2	Q92AFP	11
SP_wrebeliae	183	3	Q92AFQ	12
SP_merriamii	186	2	Q92AFR	13
SP_barberry13	186	2	Q92AFS	14
SP_tunagi	203	2	Q92AFW	15
SP_invertibrata	248	2	Q92AX0	16
SP_mammal	249	5	Q92AX1	17
SP_bifer	256	2	Q92AX2	18
SP_cannabis	259	1	Q92AX4	19

POST-PROCESSING: Maximum material thickness 1000 mm. Maximum weight 1000 kg. List items 45. Standard sizes 1000 x 2000 mm.

COST PROCESSING: Minimum weight 100g
Maximum Mass of 1000g
Listing this 45 summaries

AN INSTITUTE OF LEARNING AND DEVELOPMENT

MANN

Query Match		Score		Match	
Best	Local Similarity	Best	Local Similarity	Best	Local Similarity
Matches : 5; Conservative: 0; Mismatches: 0; Insertions: 0; Deletions: 0; Gaps: 0;					
QF	1.000000	1.000000	1.000000	1.000000	1.000000
1b	103	107	103	107	103
Result : 6					
QF-FR2	Preliminary:	•	Best:	1.000000	
1b	QF-FR2				
AC	QF-FR2;				
DT	01-01-2000	(Tremblay, L., Last sequence created)			
DI	01-01-2000	(Tremblay, L., Last distinct sequence)			
HE	KIBOMAL_Protein	L33.			
IN	REF ID: CR_00577.				
IS	treponema pallidum (Treponema pallidum subsp. pallidum) M11442				
OC	Bacterium, Firmicutes, Spirochaetes, Treponematales				
OG	Mycoplasma, eukaryotes				
OX	Mycoplasma genitalium				
KN	NC_001482;				
1b	NC_001482;				
RP	SKELETON, N. A.				
RC	SKELETON, SKELETON				
RX	MBLNEP_20506219; PubMed_1163974;				
RA	Glass, J. L., Kowalewski, E. J., Gross, L.S., et al. (1997). <i>J. Clin. Microbiol.</i> , 35, 104-107.				
RA	Cassidy, D. H., et al. (1997). <i>J. Clin. Microbiol.</i> , 35, 104-107.				
RT	*the complete sequence of the mycoplasma genome of <i>Treponema pallidum</i> subsp. <i>pallidum</i> (Treponema pallidum) is available at: http://www.ncbi.nlm.nih.gov .				
RI	http://www.ncbi.nlm.nih.gov				
Query Match					
Best	Local Similarity	Score	Match	Best	Local Similarity
Matches : 6; Conservative: 0; Mismatches: 0; Insertions: 0; Deletions: 0; Gaps: 0;					
QF	1.000000	1.000000	1.000000	1.000000	1.000000
1b	103	107	103	107	103
Result : 8					
QF-FR2	Preliminary:	•	Best:	1.000000	
1b	QF-FR2;				
AC	QF-FR2;				
DT	01-01-2000	(Tremblay, L., Last sequence created)			
DI	01-01-2000	(Tremblay, L., Last distinct sequence)			
HE	KIBOMAL_Protein	L33.			
IN	REF ID: CR_00577.				
IS	treponema pallidum (Treponema pallidum subsp. pallidum) M11442				
OC	Bacterium, Firmicutes, Spirochaetes, Treponematales				
OG	Mycoplasma, eukaryotes				
OX	Mycoplasma genitalium				
KN	NC_001482;				
1b	NC_001482;				
RP	SKELETON, N. A.				
RC	SKELETON, SKELETON				
RX	SPINNIE, P. M., KOWALEWSKI, E. J., GROSS, L. S., et al. (1997). <i>J. Clin. Microbiol.</i> , 35, 104-107.				
RA	CASSIDY, D. H., et al. (1997). <i>J. Clin. Microbiol.</i> , 35, 104-107.				
RA	*the complete sequence of the mycoplasma genome of <i>Treponema pallidum</i> subsp. <i>pallidum</i> (Treponema pallidum) is available at: http://www.ncbi.nlm.nih.gov .				
RI	http://www.ncbi.nlm.nih.gov				

1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100